JP2012082213A5 - - Google Patents

Download PDF

Info

Publication number
JP2012082213A5
JP2012082213A5 JP2011270382A JP2011270382A JP2012082213A5 JP 2012082213 A5 JP2012082213 A5 JP 2012082213A5 JP 2011270382 A JP2011270382 A JP 2011270382A JP 2011270382 A JP2011270382 A JP 2011270382A JP 2012082213 A5 JP2012082213 A5 JP 2012082213A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
composition according
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011270382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012082213A (ja
JP5509185B2 (ja
Filing date
Publication date
Priority claimed from US10/354,090 external-priority patent/US20040210035A1/en
Priority claimed from US10/715,417 external-priority patent/US7892559B2/en
Application filed filed Critical
Publication of JP2012082213A publication Critical patent/JP2012082213A/ja
Publication of JP2012082213A5 publication Critical patent/JP2012082213A5/ja
Application granted granted Critical
Publication of JP5509185B2 publication Critical patent/JP5509185B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011270382A 2003-01-30 2011-12-09 スルビビン誘導ペプチドおよびその使用 Expired - Lifetime JP5509185B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/354,090 US20040210035A1 (en) 2002-01-30 2003-01-30 Survivin-derived peptides and use thereof
US10/354,090 2003-01-30
US10/715,417 2003-11-19
US10/715,417 US7892559B2 (en) 2002-01-30 2003-11-19 Survivin-derived peptides and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005518634A Division JP5121143B2 (ja) 2003-01-30 2004-01-30 スルビビン誘導ペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2012082213A JP2012082213A (ja) 2012-04-26
JP2012082213A5 true JP2012082213A5 (enExample) 2012-07-12
JP5509185B2 JP5509185B2 (ja) 2014-06-04

Family

ID=46241465

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011270382A Expired - Lifetime JP5509185B2 (ja) 2003-01-30 2011-12-09 スルビビン誘導ペプチドおよびその使用
JP2012117831A Expired - Lifetime JP5931585B2 (ja) 2003-01-30 2012-05-23 スルビビン誘導ペプチドおよびその使用
JP2015011806A Expired - Lifetime JP6021961B2 (ja) 2003-01-30 2015-01-23 スルビビン誘導ペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012117831A Expired - Lifetime JP5931585B2 (ja) 2003-01-30 2012-05-23 スルビビン誘導ペプチドおよびその使用
JP2015011806A Expired - Lifetime JP6021961B2 (ja) 2003-01-30 2015-01-23 スルビビン誘導ペプチドおよびその使用

Country Status (7)

Country Link
EP (1) EP2857035B1 (enExample)
JP (3) JP5509185B2 (enExample)
CN (1) CN103288920B (enExample)
DK (1) DK2359841T3 (enExample)
ES (3) ES2633389T3 (enExample)
NO (2) NO343244B1 (enExample)
PT (1) PT2359841E (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
JPWO2021024742A1 (enExample) * 2019-08-06 2021-02-11

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
EP1066527A2 (en) * 1998-04-01 2001-01-10 Yale University Method to identify modulators of survivin - tubulin interaction
WO2000003693A1 (en) * 1998-07-14 2000-01-27 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
RU2367468C2 (ru) * 2003-11-19 2009-09-20 Мерк Патент Гмбх БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ

Similar Documents

Publication Publication Date Title
US20250223335A1 (en) Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
ES2860798T3 (es) Nuevos péptidos y nuevas combinaciones de péptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cáncer
AU2016335177B2 (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
TWI758912B (zh) 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
JP2020182477A (ja) 養子細胞療法のための腫瘍浸潤リンパ球
ES2952959T3 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003)
UA124575C2 (uk) Пептид для лікування раку
BR112019020959A2 (pt) peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
EP3273986A1 (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
BR112019015237A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de ovário e outros cânceres
AU2017229149A1 (en) Uterine cancer treatments
CA3072922A1 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TW200930402A (en) Cancer vaccine composition
AU2022204032B2 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
CA3223546A1 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
BR112020027021A2 (pt) Peptídeo, anticorpo, receptor de célula t, célula hospedeira recombinante, método in vitro de produção de linfócitos t ativados, composição farmacêutica, método de produção do peptídeo, uso do peptídeo e kit
BR112019021094A2 (pt) Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres
JP2010521441A5 (enExample)
JP2012082213A5 (enExample)
BR112021010432A2 (pt) Peptídeo, anticorpo, receptor de célula t, aptâmero, ácido nucleico, célula hospedeira, método in vitro de produção de linfócitos t ativados, llinfócito t, composição farmacêutica, método de produção de um peptídeo e de produção de uma vacina anticâncer, método para matar células alvo em um paciente, utilização e kit
ES2896919T3 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (CHC) y otros tipos de cáncer
TWI755365B (zh) 用於小細胞肺癌和其他癌症免疫治療的新型肽和肽組合物
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
Liu et al. Prediction and identification of B cell epitopes derived from EWS/FLI-l fusion protein of Ewing’s sarcoma
TWI772927B (zh) 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架